{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gutierrez-Gutierrez B"],"funding":["Plan nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III (ISCIII), Subdirección General de Redes y Centros de Investigacion Cooperativa, Ministerio de Ciencia, Innovacion y Universidades","Spanish Ministry of Science and Innovation, ISCIII"],"pagination":["e0110221"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8522723"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["65(11)"],"pubmed_abstract":["There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing <i>Enterobacterales</i> (ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treatment with ertapenem or meropenem and clinical cure in KT recipients with nonsevere bacteremic urinary tract infections (B-UTI) caused by ESBL-E. We performed a registered, retrospective, international (29 centers in 14 countries) cohort study (INCREMENT-SOT, NCT02852902). The association between targeted therapy with ertapenem versus meropenem and clinical cure at day 14 (the principal outcome) was studied by logistic regression. Propensity score matching and desirability of outcome ranking (DOOR) analyses were also performed. A total of 201 "],"journal":["Antimicrobial agents and chemotherapy"],"pubmed_title":["Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing <i>Enterobacterales</i> in Kidney Transplant Recipients."],"pmcid":["PMC8522723"],"funding_grant_id":["FIS PI18/01849","FIS PI16/01631","CP 18/00073","REIPI RD16/0016/0001"],"pubmed_authors":["Rana MM","Lepe JA","Rizzi M","Clemente WT","Paul M","van Delden C","Merino E","Torre-Cisneros J","Carratala J","Steinke SM","Aguado JM","Tufan ZK","Perez-Galera S","Kazak E","Corbella L","Farinas MC","Investigators from the REIPI/ESGICH/ESGBIS/INCREMENT-SOT Group","Montejo M","Seminari EM","Iyer RN","Oriol I","Fernandez-Ruiz M","Roilides E","Tan BH","Abdala E","Mularoni A","Munoz P","Fortun J","Soldani F","Gunseren F","Rodriguez-Bano J","Pilmis B","Pascual A","Arslan H","Cordero E","Natera AM","Lease ED","Coussement J","Pierrotti LC","Gutierrez-Gutierrez B","Loeches B","Lowman W","Grossi PA","Bodro M","Martinez-Martinez L","Perez-Nadales E","Eriksson BM","David MD"],"additional_accession":[]},"is_claimable":false,"name":"Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing <i>Enterobacterales</i> in Kidney Transplant Recipients.","description":"There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing <i>Enterobacterales</i> (ESBL-E) in kidney transplant (KT) recipients. We evaluated the association between treatment with ertapenem or meropenem and clinical cure in KT recipients with nonsevere bacteremic urinary tract infections (B-UTI) caused by ESBL-E. We performed a registered, retrospective, international (29 centers in 14 countries) cohort study (INCREMENT-SOT, NCT02852902). The association between targeted therapy with ertapenem versus meropenem and clinical cure at day 14 (the principal outcome) was studied by logistic regression. Propensity score matching and desirability of outcome ranking (DOOR) analyses were also performed. A total of 201 ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2026-06-07T03:21:47.521Z","creation":"2025-04-05T15:22:14.817Z"},"accession":"S-EPMC8522723","cross_references":{"pubmed":["34370578"],"doi":["10.1128/aac.01102-21","10.1128/AAC.01102-21"]}}